Quick Answer
AbbVie Inc. reported Cash And Cash Equivalents At Carrying Value of $5.23 billion for the year ending 2025.
- AbbVie Inc. showed a decrease of -5.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from AbbVie Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), AbbVie Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 52,190.0%.
- Historical annual values: Fiscal year 2025: $5.23 billion | Fiscal year 2024: $5.52 billion | Fiscal year 2023: $12.81 billion | Fiscal year 2022: $9.20 billion | Fiscal year 2021: $9.75 billion | Fiscal year 2020: $8.45 billion | Fiscal year 2019: $39.92 billion | Fiscal year 2018: $7.29 billion | Fiscal year 2017: $9.30 billion | Fiscal year 2016: $5.10 billion | Fiscal year 2015: $8.40 billion | Fiscal year 2014: $8.35 billion | Fiscal year 2013: $9.60 billion | Fiscal year 2012: $5.90 billion | Fiscal year 2011: $27.00 million | Fiscal year 2010: $10.00 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: